Theralase Technologies Inc.  

(Public, CVE:TLT)   Watch this stock  
Find more results for TLT
+0.005 (1.41%)
May 30 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.35 - 0.36
52 week 0.25 - 0.45
Open 0.36
Vol / Avg. 24,500.00/113,917.00
Mkt cap 38.54M
P/E     -
Div/yield     -
EPS -0.06
Shares 107.05M
Beta 1.07
Inst. own     -

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -108.08% -267.74%
Operating margin -108.08% -267.74%
EBITD margin - -263.07%
Return on average assets -52.67% -95.39%
Return on average equity -59.23% -108.26%
CDP Score - -


1945 Queen St E
+1-416-6995273 (Phone)
+1-416-6995250 (Fax)

Website links


Theralase Technologies Inc. is a Canada-based designer, developer, manufacturer and marketer of super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Company's technology platform targets healthcare sectors: for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; wound care and healing, and research and development (R&D) into combining patented photodynamic compounds with patented, super-pulsed, biofeedback laser technology to attack targeted cancers, bacteria and viruses. The Company is organized into two operating divisions. The Therapeutic Laser Technology division is responsible for all aspects of the Company's therapeutic laser business. The Photo Dynamic Therapy division is responsible for the R&D of Photo Dynamic Compounds (PDCs) for the destruction of primarily cancer.

Officers and directors

Roger Dumoulin-White President, Chief Executive Officer, Director
Kristina Hachey Chief Financial Officer
Michael Borovec Director of Investor Relations
Matthew Perraton Director
Guy John Anderson Independent Director
Age: 1
Randall Bruder Independent Director